Navigation Links
Role of Hsp 104 in the Spread of Prion Diseases

Protein’s role in the spread of the lethal Prion diseases has been brought to light by researchers from Brown University//. This was published in an online edition of PLoS Biology.

Researchers under Tricia Serio have revealed that the protein Hsp 104 is responsible for the spread and multiplication of Prion diseases. This protein breaks up groups of such infectious proteins leading to the fatal disorders of the brain.

According to Serio, the protein fragmentation helped them understand the spreading of Prion diseases and their role in diseases like Parkinsons.

Prions are nothing but infectious particles of proteinaceous nature which cannot be inactivated by measures which modify nucleic acids. They cause many disorders of infectious and genetic nature.

Prion diseases are characterized by loss of motor control, dementia, paralysis and death, a pattern similar to pneumonia. Scrapie was the first Prion disease to have been discovered.
JYT
'"/>




Page: 1

Related medicine news :

1. Spreading its wings
2. Smallpox Would Spread Rapidly
3. Spreading knowledge to doctors about herbal medicine
4. Stopping Prostate Cancer from Spreading
5. Drug might prevent Prostate Cancer Spread
6. Circumcision Found To Prevent HIV Spread
7. New Way to Detect Spread of Skin Cancer
8. The Logic Behind The Spread Of SARS
9. Vaccine To Stop the Spread of Chickenpox
10. Minimizing The Risk Of HIV Spread
11. Drug might prevent Prostate Cancer Spread
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Role Hsp the Spread Prion Diseases

Other Medicine News:Health News:Ortho Organizers(R) Introduces Product Line Extension - Rectangular Super Elastic Nitanium(R) Black Ti(TM) Archwire 2Health News:Catalyst Pharmaceutical Partners Announces Positive Phase II Trial Results for Vigabatrin in the Treatment of Cocaine Addiction 2Health News:Catalyst Pharmaceutical Partners Announces Positive Phase II Trial Results for Vigabatrin in the Treatment of Cocaine Addiction 3Health News:Catalyst Pharmaceutical Partners Announces Positive Phase II Trial Results for Vigabatrin in the Treatment of Cocaine Addiction 4Health News:Catalyst Pharmaceutical Partners Announces Positive Phase II Trial Results for Vigabatrin in the Treatment of Cocaine Addiction 5Health News:Most ancient case of tuberculosis found in 500,000-year-old human; points to modern health issues 2Health News:AMAS Test Measures Lethal Replikin Gene Activity in Lung and Other Cancers 2Health News:AMAS Test Measures Lethal Replikin Gene Activity in Lung and Other Cancers 3Health News:Dr. William McGuire Settles with the SEC and the UnitedHealth Group Special Litigation Committee on Stock Options Matter 2Health News:Dr. William McGuire Settles with the SEC and the UnitedHealth Group Special Litigation Committee on Stock Options Matter 3Health News:Green Tea, Fruit Extracts Touted as Potential Cancer Fighters 2Health News:Green Tea, Fruit Extracts Touted as Potential Cancer Fighters 3
Breaking Medicine Technology:Al Novak Elected Chairman of the Board of OrbusNeich Medical 2National Ergonomics Expo Sees Immediate 93% Exhibit Space Renewal for 2010; Equipois, Herman Miller, Neutral Posture, REDpoint International Win 2009 Attendees' Choice New Product Awards 2PRA International Hosts an Infectious Diseases Audio Conference 2PRA International Hosts an Infectious Diseases Audio Conference 3Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 1Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 2Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 3Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 4Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 5Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 6Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 7Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 8Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 9Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 10Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 11Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 12Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 13Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 14Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 15Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 16Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 17Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 18Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 19Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 20Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 21Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 22Los Angeles Kerlan Jobe Orthopaedic Clinic Pays 243 Million to Settle Kickback Allegations 62394 1Los Angeles Kerlan Jobe Orthopaedic Clinic Pays 243 Million to Settle Kickback Allegations 62394 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately 2457 Million 15034 1PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately 2457 Million 15034 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately 2457 Million 15034 3